logo-loader
viewhVIVO PLC

hVIVO successfully conducts challenge study in older people

The process was specifically designed to provide the drug developers with an early clinical proof-of-concept platform to safely evaluate potential treatments in this vulnerable population

AIM -
Developing in late autumn through to early spring, RSV causes cold, which may then turn into bronchiolitis or pneumonia

hVIVO PLC (AIM: HVO) said it has successfully conducted a human challenge study in older people for the respiratory syncytial virus, or RSV.

Challenge studies involve intentionally but safely infecting healthy people in a controlled environment to assess their response to certain drugs. hVIVO recruited a group of  60 to 75-year-olds, who were monitored at the company’s special facility in London.

Researchers established the firm’s RSV challenge model could be conducted safely in an older population.

The process was specifically designed to provide the drug developers with an early clinical proof-of-concept platform to safely evaluate potential treatments in this vulnerable population, hVIVO said. 

“The company's contract pipeline is experiencing strong demand for RSV challenge study services and we anticipate this demand will continue reflective of the unmet medical need that companies are addressing," said chief executive, Dr Trevor Phillips.

Developing in late autumn through to early spring, RSV causes cold, which may then turn into bronchiolitis or pneumonia.

Quick facts: hVIVO PLC

Price: 16.5 GBX

LSE:HVO
Market: LSE
Market Cap: £13.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

on 10/12/19

RNS

Rule 2.9 Announcement

1 week, 3 days ago

Offer Wholly Unconditional

1 week, 3 days ago

Open Orphan

1 week, 5 days ago

Rule 2.9 Announcement

1 week, 5 days ago

Second Closing of the Offer

1 week, 6 days ago

Rule 2.9 Announcement

2 weeks ago

2 min read